RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. PRGS
8. VKTX
9. CMPX
10. GS

Go back to RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn

August 20, 2024 8:40 AM EDT

(Updated - August 20, 2024 11:13 AM EDT)

Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has struck an agreement to acquire V-Wave Ltd., a privately-held company specializing in treatments for heart failure.

The deal will see Johnson & Johnson make an upfront payment of $600 million, with the potential for an additional $1.1 billion in milestone payments.

V-Wave will join Johnson &... More

Johnson & Johnson gets green light for lung cancer combination treatment

August 20, 2024 7:49 AM EDT

Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a combination treatment of RYBREVANT and LAZCLUZE for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.

According to the company, it... More